Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunofree is a polyherbal Ayurvedic proprietary medicine developed as an antiviral and immunomodulatory therapy, primarily investigated for the treatment of mild to moderate COVID-19. The formulation contains 15 specific herbal extracts, including Kalmegh (*Andrographis paniculata*), Bhumyamalaki (*Phyllanthus niruri*), Licorice (*Glycyrrhiza glabra*), and Artemisia (*Damanaka*), which are traditionally used for respiratory health and immune support. The drug is designed to reduce viral load and manage symptoms by inhibiting viral replication and modulating the body's inflammatory response. It was evaluated in clinical trials (such as NCT04494204) in combination with Reginmune, demonstrating potential in speeding up recovery and clearing viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Immunofree.